VRTX
$144.64
Vertex Pharmaceutic
($2.77)
(1.88%)
VRTX
Earnings Whisper ®
N/A
4th Quarter December 2017
Consensus:  $0.29
Revenue:  $588.78 Mil
Wednesday
Jan 24
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Wednesday, October 25, 2017

What do you expect when VRTX reports earnings?
Beat
Meet
Miss

Where is VRTX's stock price going from here?
Up
Flat
Down
Stock chart of VRTX
Analysts
Summary of analysts' recommendations for VRTX
Score
Grade
Pivots
Resistance
$150.95
$149.21
$146.92

$145.18

Support
$142.89
$141.15
$138.86
Tweet
Growth
Description
Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)
Peers
CelgeneRegeneron PharmaceuticalsBioMarin PharmaceuticalJohnson & JohnsonUltragenyx PharmaceuticalEndo International plcInterCeptEli LillyZoetisBristol-Myers Squibb